JP2009529576A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529576A5
JP2009529576A5 JP2009500402A JP2009500402A JP2009529576A5 JP 2009529576 A5 JP2009529576 A5 JP 2009529576A5 JP 2009500402 A JP2009500402 A JP 2009500402A JP 2009500402 A JP2009500402 A JP 2009500402A JP 2009529576 A5 JP2009529576 A5 JP 2009529576A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
virus
composition according
highly conserved
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/006113 external-priority patent/WO2007106404A2/en
Publication of JP2009529576A publication Critical patent/JP2009529576A/ja
Publication of JP2009529576A5 publication Critical patent/JP2009529576A5/ja
Pending legal-status Critical Current

Links

Images

JP2009500402A 2006-03-10 2007-03-09 持続感染または潜伏感染を引き起こすウイルスに対するワクチン Pending JP2009529576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78112306P 2006-03-10 2006-03-10
PCT/US2007/006113 WO2007106404A2 (en) 2006-03-10 2007-03-09 Vaccine for viruses that cause persistent or latent infections

Publications (2)

Publication Number Publication Date
JP2009529576A JP2009529576A (ja) 2009-08-20
JP2009529576A5 true JP2009529576A5 (enExample) 2010-04-30

Family

ID=38510006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500402A Pending JP2009529576A (ja) 2006-03-10 2007-03-09 持続感染または潜伏感染を引き起こすウイルスに対するワクチン

Country Status (5)

Country Link
US (1) US8501194B2 (enExample)
EP (1) EP2001516A4 (enExample)
JP (1) JP2009529576A (enExample)
CA (1) CA2645507A1 (enExample)
WO (1) WO2007106404A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699756A1 (en) * 2007-09-21 2009-03-26 Sanofi Pasteur Vaccine composition for the prevention of cmv infection
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
US8979890B2 (en) 2010-10-01 2015-03-17 Ethicon Endo-Surgery, Inc. Surgical instrument with jaw member
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
CA2826199A1 (en) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
EP2726097A4 (en) * 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
US9365832B2 (en) * 2012-01-09 2016-06-14 Sanofi Pasteur Biologics, Llc Purification of herpes virus
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
EP2929034A4 (en) * 2012-12-04 2016-06-22 Merck Sharp & Dohme VIRUS VECTORS WITH CONDITIONAL REPLICATION
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
US10314383B2 (en) 2015-03-30 2019-06-11 Gary McClellan Thompson Wearable sports equipment carrier with personal flotation device
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
EP3677593B1 (en) * 2017-08-30 2024-08-07 KM Biologics Co., Ltd. Modified hsv gb protein and hsv vaccine including same
ES3005559T3 (en) * 2018-07-20 2025-03-14 Aicuris Anti Infective Cures Ag Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4147712A1 (en) * 2021-09-13 2023-03-15 OncoDNA Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
CA3230564A1 (en) * 2021-09-13 2023-03-16 Jean-Pol DETIFFE Method to generate personalized neoantigens of a tumor of a patient
WO2025221890A1 (en) * 2024-04-16 2025-10-23 Mirror Biologics, Inc. Methods and compositions for improving the immune response against viral pathogens

Similar Documents

Publication Publication Date Title
CN112618707B (zh) 一种SARS-CoV-2冠状病毒疫苗及其制备方法
Del Val et al. Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89
AU2017297610B2 (en) Compositions and methods for alphavirus vaccination
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
KR101702956B1 (ko) 다수의 상동성 뉴클레오티드 서열을 포함하는 벡터
JP7579245B2 (ja) 組成物及び方法
CN113201507B (zh) 一种重组的伪狂犬病病毒及其疫苗组合物
CN104271745A (zh) 用于治疗巨细胞病毒的组合物和方法
PT2753364T (pt) Citomegalovirus de replicação condicional como uma vacina para cmv
CN109415705A (zh) 组合初免:加强免疫疗法
CN115845042A (zh) 重组新型冠状病毒s蛋白三聚体疫苗组合物及其应用
KR20230022206A (ko) 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신
CN111154778B (zh) 禽新城疫病毒新型基因工程亚单位疫苗
WO2023236822A1 (zh) H5n6禽流感广谱性疫苗的开发及其应用
US12599658B2 (en) Hepatitis B virus-specific T cell responses
CN121752290A (zh) Dev作载体的禽流感h9疫苗
EP1624890A2 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
WO2023207717A1 (zh) H5n8禽流感广谱性疫苗的开发及其应用
CN114369580B (zh) 重组hvt及其用途
CN116549627A (zh) 基于腺病毒载体的广谱新冠疫苗及其应用
WO2023092023A2 (en) Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19)
Li et al. Construction and anti-tumor effects of recombinant fowlpox virus expressing Newcastle disease virus hemagglutinin-neuramidinase gene
CN113308440B (zh) 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用
RU2850187C1 (ru) РЕКОМБИНАНТНЫЙ ГЕРПЕСВИРУС ИНДЕЕК (rHVT), СОДЕРЖАЩАЯ ЕГО ВАКЦИНА И ЕГО ПРИМЕНЕНИЕ
EP1398380A1 (en) Orthopoxvirus antigens and use thereof